Internationally renowned neuroscience specialist, Professor Andrew Maas to visit Melbourne

17 February

Professor Andrew Maas, with the support of veski, Monash University and the University of Melbourne, will visit Melbourne in March 2017 to share candid insights, experiences and advice on his journey from research and clinic to the manager of a global collaboration program and international representative positions in his field. 

veski is proud to deliver three exclusive events with Prof. Maas for members of the veski connection community to hear directly from one of the world’s foremost scientists. 

  • The invitation-only veski conversation will connect Prof. Maas with Australian leaders and practitioners in the traumatic brain injury space;
  • A veski masterclass for senior and mid-level researchers interested in growing their leadership and enterprise skills; and
  • A veski kickstart event for Victorian PhD and early-career researchers to learn more about opportunities in industry and how to develop a sustainable career path. 

Prof. Maas is a general neurosurgeon with a specific interest in Traumatic Brain Injury and neuro-intensive care.

Professor and Chairman of the Department of Neurosurgery at the Antwerp University Hospital and University of Antwerp, Prof Maas is the Project Coordinator of the CENTER-TBI.  In this role, he acts as the intermediary between the European Commission and the Consortium and as such is responsible for all scientific activities of the consortium. He holds positions as the Past President of the International Neurotrauma Society, Co-Chairman of the European Brain Injury Consortium and member of the Neurotraumatology Committee of the World Federation of Neurosurgical Societies.

Prof. Maas’ main research interests are:

  • Clinical trial design and analysis in Traumatic Brain Injury
  • Prognosis in Traumatic Brain Injury
  • Individualized Targeted Management in Neurocritical care
  • Quality of Life after brain injury
  • Standardization of data collection

 

CENTRE-TBI  www.center-tbi.eu/

CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI) is a large collaborative project funded by the European Commission. Its aim is to improve the care for patients with TBI. It represents a focussed European effort, with 37 participating organisations and 10 associated participants across Europe and including representatives from North America, Australia, New Zealand and China. The project is designed as a comparative effectiveness research (CER) study with a strong emphasis on evidence translation and communication, aiming to achieve optimal dissemination of results.

CENTRE-TBI stemmed from a workshop in Brussels hosted by the European Commission and NIH/NINDS on the “feasibility and benefits of international collaboration in the field of TBI research”. It brought together over 60 policy makers, scientists, clinicians and patient and industry representatives to identify gaps in our knowledge of TBI and summarize research priorities.

Research priorities identified included:

  • Comparative effectiveness research to determine the benefits of current and new treatments
  • Prediction of outcome and how this is affected by patient injury and the quality of general and specific management across the continuum of care
  • Development and validation of surrogate markers of injury and recovery
  • A patho-anatomical and mechanistic patient classification system to enable targeted therapies

These research priorities are embodied in the CENTER-TBI project. Results from the CENTER-TBI studies will deliver profound impacts in terms of treatment provision (Precision Medicine and personalized management), health care policy (improved organisation and quality assessment), economy (improved cost-effectiveness), and most importantly, improved health, quality of life, and social integration for patients. 

 

What's On

S M T W T F S
 
 
 
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30